High-Dose Wegovy Linked to Significantly Higher Risk of Sudden Sight Loss and "Eye Stroke" Compared to Other Semaglutide Medications

New analysis finds Wegovy users have significantly higher odds of sudden sight loss, with the risk being three times greater in men than in women.

By: AXL Media

Published: Mar 12, 2026, 11:23 AM EDT

Source: Information for this report was sourced from BMJ Group

Identifying a Potent Ocular Side Effect in Weight-Loss Drugs

New research into the safety profile of GLP-1 receptor agonists has identified a troubling link between the high-dose weight-loss drug Wegovy and a rare condition known as "eye stroke." Ischaemic optic neuropathy (ION) occurs when blood flow to the optic nerve is interrupted, leading to sudden and often permanent vision loss. While various forms of semaglutide have been used to treat diabetes and obesity for years, this latest study indicates that Wegovy carries the highest risk among its peers. Researchers analyzed over 30 million reports from the US Food and Drug Administration (FDA) to pinpoint whether specific formulations or dosages influenced the frequency of these ocular complications.

Comparative Risks Between Wegovy and Ozempic

The study highlights a stark contrast in safety signals between Wegovy, which is approved for obesity at a 2.4 mg weekly dose, and Ozempic, used for type 2 diabetes at lower dosages. Despite Ozempic having a much longer market history and seven times more total adverse event reports, the odds of developing ION were found to be nearly five times higher with Wegovy. Scientists believe that the higher concentration of the drug in Wegovy may predispose patients to low blood supply in the optic nerve. This "hypoperfusion" is likely driven by factors such as low blood pressure and autonomic instability, though a direct clinical link is still being investigated.

Significant Gender Disparity in Reported Vision Loss

In a notable finding for clinical practitioners, the risk of developing an eye stroke while using these medications appears to be heavily influenced by the patient’s sex. The analysis indicated that the odds of ION are more than three times higher in men than in women. Specifically, the data showed 116 times greater odds for men using Wegovy compared to those not taking the drug. While women also showed an increased risk, particularly with Ozempic, the signal in the male population was significantly more pronounced. This disparity suggests that prescribing physicians may need to be more vigilant when monitoring the ocular health of male patients on high-dose semaglutide regimens.